BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 20.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,163 shares of the biotechnology company’s stock after selling 11,989 shares during the quarter. Moody National Bank Trust Division’s holdings in BioCryst Pharmaceuticals were worth $414,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Allianz Asset Management GmbH boosted its stake in shares of BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 1,200 shares during the period. Royal Bank of Canada lifted its holdings in BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after buying an additional 1,458 shares in the last quarter. SG Americas Securities LLC boosted its position in BioCryst Pharmaceuticals by 5.2% in the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 2,146 shares during the period. Wellington Management Group LLP grew its stake in shares of BioCryst Pharmaceuticals by 2.6% in the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after acquiring an additional 2,291 shares in the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of BioCryst Pharmaceuticals by 38.2% during the fourth quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 4,097 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of the firm’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director owned 65,352 shares in the company, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by corporate insiders.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $7.70 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.01 and a 12 month high of $11.31. The stock has a market capitalization of $1.62 billion, a P/E ratio of -42.78, a P/E/G ratio of 1.55 and a beta of 1.13. The business has a 50 day simple moving average of $8.32 and a 200-day simple moving average of $8.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. During the same quarter in the previous year, the company posted ($0.06) EPS. The company’s revenue was up 49.5% compared to the same quarter last year. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BCRX shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Wedbush upped their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 30th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Finally, Bank of America boosted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.